Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2016

View Archived Issues

Syndax Pharmaceuticals and UCB enter exclusive worldwide license agreement for UCB-6352

Janssen Biotech exercises option within global license agreement with OSE Immunotherapeutics

Lysogene enrolls first patient in SAMOS study

First clinical data reported for novel ketolide WCK-4873

Positive topline results from phase IIb trial of vobarilizumab as monotherapy in RA

Bayer Healthcare develops Mnk1 inhibitors

ArmaGen signs collaboration with Rett Syndrome Research Trust

Forendo Pharma Oy patents 17beta-HSD1 inhibitors

Akarna Therapeutics discloses farnesoid X receptor agonists

Takeda Pharmaceutical presents GluN2B receptor inhibitors

Galderma Pharma divulges chemokine receptor antagonists

Rugen Holdings Cayman patent reports GluN2B antagonists

MicuRx Pharmaceuticals introduces antibacterial compounds

Seres Therapeutics begins phase Ib trial of microbiome therapeutic

CSI Laboratories launches a novel comprehensive PD-L1 expression assay

FDA issues complete response letter for Aggrastat in new STEMI indication

FDA grants fast track designation to idalopirdine

FDA approves Xolair for children with allergic asthma

Anti-apoE4 MAb 9D11 prevents beta-amyloid accumulation in vivo

Ribaxamase approved as generic name for Synthetic Biologics' SYN-004

Alnylam initiates phase I/II trial of ALN-HBV to treat chronic HBV infection

FDA places clinical hold on phase II ROCKET trial of JCAR-015 following patient deaths

TherapeuticsMD submits NDA for Yuvvexy for dyspareunia

GON4L identified as potential cancer biomarker and therapeutic target

Pivotal phase III data reported for deutetrabenazine in Huntington's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...